  <div class="data-description" style="background-color: #f2f2f2; padding: 10px;">
    <h4>Data Descriptions:</h4>
    <br>
    <p>PC9, 4492 sequenced cells (EGFR Del19, activating mutation, PMID: Simonetti et al. (2010))
      <a href="https://pubmed.ncbi.nlm.nih.gov/21167064/" target="_blank">PMID: Simonetti et al. (2010)</a>
    </p>
    <br>
    <p>A549, 6898 sequenced cells (KRAS p.G12S, growth and proliferation, PMID: Yoon et al. (2010))
      <a href="https://pubmed.ncbi.nlm.nih.gov/20358631/" target="_blank">PMID: Yoon et al. (2010)</a>
    </p>
    <br>
    <p>NCI-H596 (HTB178), 2965 sequenced cells (MET Del14 , enhanced protection from apoptosis and cellular migration, PMID: Cerqua et al. (2022))
      <a href="https://pubmed.ncbi.nlm.nih.gov/35636967/" target="_blank">PMID: Cerqua et al. (2022)</a>
    </p>
    <br>
    <p>NCI-H1395 (CRL5868), 2673 sequenced cells (BRAF p.G469A, gain of function, resistant to all tested MEK +/âˆ’ BRAF inhibitors, PMID: Negrao et al. (2020))
      <a href="https://pubmed.ncbi.nlm.nih.gov/32540409/" target="_blank">PMID: Negrao et al. (2020)</a>
    </p>
    <br>
    <p>DV90, 2998 sequenced cells (ERBB2 p.V842I, increases kinase activity, PMID: Boese et al. (2013))
      <a href="https://pubmed.ncbi.nlm.nih.gov/23220880/" target="_blank">PMID: Boese et al. (2013)</a>
    </p>
    <br>
    <p>HCC78, 2748 sequenced cells (SLC34A2-ROS1 Fusion, ROS1 inhibitors have antiproliferative effect, PMID: Davies et al. (2012))
      <a href="https://pubmed.ncbi.nlm.nih.gov/22919003/" target="_blank">PMID: Davies et al. (2012)</a>
    </p>
    <br>
    <p>CCL.185.IG, 6354 sequenced cells
      <a href="https://www.atcc.org/products/ccl-185ig" target="_blank">EML4-ALK Fusion-A549 Isogenic Cell</a>
    </p>
  </div>

